Literature DB >> 34985668

HIV Reservoirs: Modeling, Quantification, and Approaches to a Cure.

Amir Dashti1, Vidisha Singh1, Ann Chahroudi2.   

Abstract

Biomedical research in animal models depends heavily on nonhuman primates (NHP) (Phillips et al., Am J Primatol 76(9):801-827, 2014). In their physiology, neurobiology, and, most importantly, their susceptibility to infectious diseases and subsequent immune responses, NHPs have many parallels with humans (Rhesus Macaque Genome Sequencing and Analysis Consortium et al., Science 316(5822):222-234, 2007). Different species of NHPs have served as important animal models for numerous infectious diseases spanning a wide range of pathogens (Gardner and Luciw, ILAR J 49(2):220-255, 2008). As a result of recognizing their utility in HIV research, NHPs have contributed to groundbreaking studies of disease pathogenesis, vaccination, and curative research (London et al., Lancet 2(8355):869-873, 1983; Henrickson et al., Lancet 1 (8321):388-390, 1983). Many African NHPs are considered natural hosts for SIV in which SIV infection is usually nonprogressive and does not cause acquired immunodeficiency syndrome (AIDS) (Chahroudi et al., Science 335(6073):1188-1193, 2012; Taaffe et al., J Virol 84(11):5476-5484, 2010). However, cross-species transmission of SIV strains to other NHPs or to humans (nonnatural hosts) leads to progressive disease and AIDS (Paiardini et al., Annu Rev Med 60:485-495, 2009). In particular, SIV infection of Asian rhesus macaques recapitulates many features of HIV infection in humans and therefore has become a widely used approach for contemporary HIV research into virus persistence and cure strategies (Gardner and Luciw, FASEB J 3(14):2593-2606, 1989). There are multiple factors that should be considered in HIV/SIV studies using NHPs including the particular monkey species and geographic background, age and sex, certain genetic properties, virus strain, route and dose of infection, interventional treatments, and prespecified study outcomes. Here, we discuss consideration of these factors to address specific questions in HIV cure research.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cure strategies; HIV; NHP; Rhesus macaques; SHIV; SIV

Mesh:

Year:  2022        PMID: 34985668     DOI: 10.1007/978-1-0716-1871-4_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  28 in total

Review 1.  Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention.

Authors:  V M Hirsch; J D Lifson
Journal:  Adv Pharmacol       Date:  2000

2.  The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication.

Authors:  Levi J Yant; Thomas C Friedrich; Randall C Johnson; Gemma E May; Nicholas J Maness; Alissa M Enz; Jeffrey D Lifson; David H O'Connor; Mary Carrington; David I Watkins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 3.  Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.

Authors:  Rowena E Johnston; Mary M Heitzeg
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 4.  Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.

Authors:  Gregory Q Del Prete; Jeffrey D Lifson; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

5.  Sex differences in HIV-1 viral load and progression to AIDS.

Authors:  H Farzadegan; D R Hoover; J Astemborski; C M Lyles; J B Margolick; R B Markham; T C Quinn; D Vlahov
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

Review 6.  Sex-based differences in HIV type 1 pathogenesis.

Authors:  Marylyn M Addo; Marcus Altfeld
Journal:  J Infect Dis       Date:  2014-07-15       Impact factor: 5.226

7.  Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.

Authors:  David H O'Connor; Bianca R Mothe; Jason T Weinfurter; Sarah Fuenger; William M Rehrauer; Peicheng Jing; Richard R Rudersdorf; Max E Liebl; Kendall Krebs; Joshua Vasquez; Elizabeth Dodds; John Loffredo; Sarah Martin; Adrian B McDermott; Todd M Allen; Chenxi Wang; G G Doxiadis; David C Montefiori; Austin Hughes; Dennis R Burton; David B Allison; Steven M Wolinsky; Ronald Bontrop; Louis J Picker; David I Watkins
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 9.  Barriers to a cure for HIV in women.

Authors:  Sara Gianella; Athe Tsibris; Liz Barr; Catherine Godfrey
Journal:  J Int AIDS Soc       Date:  2016-02-18       Impact factor: 5.396

Review 10.  Sex Differences in HIV Infection.

Authors:  Eileen P Scully
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.